Derek Brandt

Investment Committee

Derek is CEO of our key partner the DCB, a global center for diabetes technology innovation dedicated to transforming diagnosis & treatment & improving quality of life for people with diabetes. He has extensive senior executive biotech, medtech & pharma experience, most recently as CEO of Sensile Medical prior to its acquisition by Gerresheimer in 2018.

Cookies

This website is using necessary cookies to provide a good browsing experience, see our Cookie Policy. These include essential cookies that are necessary for the operation of the siteor for comfort settings.

Cookies

This website is using necessary cookies to provide a good browsing experience, see our Cookie Policy. These include essential cookies that are necessary for the operation of the siteor for comfort settings.

Your cookie preferences have been saved.